Genentech Provides Update on Phase III Study of Tecentriq in Women With Advanced-stage Ovarian Cancer

SOUTH SAN FRANCISCO, Calif.– Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.

Scroll Up
error: Content is protected !!